Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–327 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of Michigan Rogel Cancer Center Clear all
Completed Not applicable Interventional Results available

A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

NCT02460835
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Adaptive Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 14, 2026, 12:20 AM EDT
Terminated Phase 2 Interventional

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling

NCT00161278
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, Gene expression profiling (analysis) of tumor samples
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 1Phase 2 Interventional

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

NCT00151086
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Vinorelbine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

NCT00645593
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine,, Cisplatin, Cetuximab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

The ConnectedCancerCare Pilot Study (CCC)

NCT03618017
View directory record Official record
Conditions
Early-stage Breast Cancer, Breast Cancer Female, Survivorship, Cancer Survivors, Transitional Care
Interventions
CCC website, Static care plan
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years to 84 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

NCT00136487
View directory record Official record
Conditions
Prostate Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
9
States / cities
Hartford, Connecticut • Boston, Massachusetts • Concord, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 14, 2026, 12:20 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

NCT00565227
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
vorinostat (suberoylanilide hydroxamic acid), docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 14, 2026, 12:20 AM EDT
Completed No phase listed Observational

Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer

NCT00603057
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 2 Interventional

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

NCT00146042
View directory record Official record
Conditions
HER-2 Positive Metastatic Breast Cancer
Interventions
Docetaxel, Trastuzumab, Erythromycin Breath Test (ERMBT)
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

NCT00456599
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine, oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 14, 2026, 12:20 AM EDT
Terminated Phase 2 Interventional

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

NCT06617455
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
Interventions
Biospecimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 12:20 AM EDT
Completed No phase listed Observational

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

NCT05583422
View directory record Official record
Conditions
Cancer
Interventions
DPYD or UGT1A1 variants
Genetic
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 14, 2026, 12:20 AM EDT
Recruiting No phase listed Observational

Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

NCT05965180
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fine Needle Photoacoustic Probe
Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer

NCT01663246
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Saliva Sample
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 14, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

NCT02400463
View directory record Official record
Conditions
Hemophagocytic Syndrome (HPS)
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 14, 2026, 12:20 AM EDT